1. N. I. Andreeva, Methodological Recommendations for the Study of the Antidepressant Activity of Pharmacological Substances. Handbook for the Experimental (Preclinical) Study of New Pharmacological Substances [in Russian], Moscow (2000).
2. O. A. Gromova, T. V. Avdeenko, and E. M. Burtsev, “Magnesium deficiency in children with minimal brain dysfunction and its correction with Magne B6,” Klin. Farmakol. Terapiya, 7, No. 3, 52–57 (1998).
3. V. V. Men’shikov, Laboratory Methods for Clinical Studies [in Russian], Meditsina, Moscow (1987).
4. A. A. Spasov, I. N. Iezhitsa, M. V. Kharitonova, and M. S. Kravchenko, “Effects of magnesium salts on the formation of depression-like behavior and anxiety in animals in conditions of dietary magnesium deficiency,” Zh. Vyssh. Nerv. Deyat. imeni I. P. Pavlova (in press).
5. N. Amyard, A. Leyris, C. Monier, H. Frances, R. G. Boulu, and J. G. Henrotte, “Brain catecholamines, serotonin and their metabolites in mice selected for low (MGL) and high (MGH) blood magnesium levels,” Magnes. Res., 8, No. 1, 5–9 (1995).